Insulet Corporation
Insulet Corporation develops insulin delivery systems for people with insulin-dependent diabetes. The companys Omnipod platform includes three products: Omnipod 5, Omnipod DASH, and Omnipod GO. Products are sold through distributors, pharmacies, and directly in various countries.
Overview
Strengths
- The company has high returns. ROIC (16.53%) is higher than the sector mean (2.97%).
- Strong EBITDA Margin of 20.45%.
Weaknesses
- With a depreciation Potential of -86.50%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Price to book ratio (19.58) is significantly higher than the sector mean (13.90).
- Analysts expect revenues to decline in the coming year.
Key Financial Data
| Indicator | Value |
|---|
| PER | 57.4 |
| EV/EBITDA | 57.7 |
| Price/Free Cash Flow' | 81.0 |
| ROIC | 16.5% |
| Net Debt/EBITDA | 1.0 |